SAN
DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the
appointment of Barbara Duncan to its
Board of Directors. Ms. Duncan brings more than 25 years of
experience as a financial executive with significant leadership
roles in the biopharmaceutical industry.
"We are delighted to welcome a leader with Barbara's extensive
biopharmaceutical industry and finance experience to the Halozyme
board," said Dr. Helen Torley,
president and chief executive officer. "Barbara's business
leadership, financial expertise and board experience will add
important insights and contributions to the continuing success and
growth of the company."
Ms. Duncan most recently served as the Chief Financial Officer
of Intercept Pharmaceuticals Inc., a biopharmaceutical company,
from 2009 to 2016. Prior to Intercept, Ms. Duncan held senior
leadership roles at DOV Pharmaceutical, Inc., a biotechnology
company, including Chief Financial Officer and Chief Executive
Officer. Prior to joining DOV, Ms. Duncan served as Vice
President of Corporate Finance -Global Healthcare at Lehman
Brothers Inc.
"It's an exciting opportunity to join Halozyme as a board member
at this juncture of their success," said Barbara Duncan. "With their disruptive
drug delivery technologies and patient centric mission, I look
forward to supporting Halozyme's continued growth and success."
Ms. Duncan holds a Master of Business Administration from the
Wharton School, University of
Pennsylvania and a Bachelor of Business Administration in
Accounting from Louisiana State
University.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme
rHuPH20, Halozyme's commercially-validated solution is used to
facilitate the delivery of injected drugs and fluids in order to
reduce the treatment burden to patients. Having touched more than
600,000 patient lives in post-marketing use in five commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical
and biotechnology companies including Roche, Takeda, Pfizer,
AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO® and
NOCDURNA® and partnered commercial products and
ongoing product development programs with several pharmaceutical
companies including Teva Pharmaceutical, Covis Pharma, Pfizer and
Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
Forward-Looking Statements
This press release may include forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts and may include projections and estimates and
their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future
financial results, events, operations, services, product
development and potential and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans", "will be" and similar expressions and include
statements in this press release related to Halozyme's intention to
redeem all of the outstanding Notes. Although Halozyme believes
that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Halozyme, that could cause actual results and
developments to differ materially from those expressed in the
forward-looking information and statements. Actual results could
differ materially from the expectations contained in these
forward-looking statements as a result of several factors. These
and other factors that may result in differences are discussed in
greater detail in the Company's most recently filed Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commission.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-barbara-duncan-to-its-board-of-directors-301739070.html
SOURCE Halozyme Therapeutics, Inc.